Unknown
PHASE2
INTERVENTIONAL
NCT02906150
Thymosin Alpha 1 Plus Maintenance Therapy With the Standard of Care (SoC) in Patients With Metastatic Non-Small Cell Lung Cancer (NSCLC), EGFR Wild Type
View on ClinicalTrials.gov
Updated Dec 15, 2025
Brief Summary
Thymosin alpha 1 plus maintenance therapy with the Standard of Care (SoC) chemotherapy plus cisplatin (or carboplatin) in patients with metastatic Non-Small Cell Lung Cancer (NSCLC), EGFR wild type
Interventions
Name:
Thymalfasin (Thymosin alpha 1, Ta1)
Type:
DRUG
Description:
Patients will be randomized to Thymosin alpha 1 plus SoC for treatment duration of 12 months. All patients will be followed for approximately 12 months or until the total number of PFS events required will be observed.
Name:
SoC (chemotherapy and platinum agent)
Type:
DRUG
Description:
Patients will be randomized to SoC for treatment duration of 12 months. All patients will be followed for approximately 12 months or until the total number of PFS events required will be observed.
Primary Outcomes
Measure:
Time to progression free survival (PFS)
TimeFrame:
Up to 12 months
Description:
Trial Information
NCT ID
NCT02906150
Status
Unknown
Study Type
INTERVENTIONAL
Phases
PHASE2
Sponsor
SciClone Pharmaceuticals
Last Updated
December 15, 2025